MISSION:

To connect patients to a cure by accelerating the discovery and delivery of precision medicine.

VISION:

Leadership in creating and delivering health informatics solutions through evidence-based approaches to predict and meet patients’ needs.

M2GEN is an oncology-focused health informatics solutions company that leverages clinical and molecular data to accelerate the discovery, development and delivery of personalized therapies. M2GEN facilitates the Oncology Research Information Exchange Network^® (ORIEN^®), a unique alliance of 18 of the nation’s leading cancer centers. ORIEN Members consent and enroll patients onto the IRB-approved protocol, Total Cancer Care^®, and share de-identified data from this study with each other and with biopharmaceutical companies via M2GEN.

Ecosystem of Shared Value

Though our approach, ORIEN Members benefit through collaborative research and shared data for learning. Our pharma partners benefit through access to the network and large-volume clinical and molecular dataset, making them better able to help design clinical trials and recruit patients. Patients ultimately benefit from active participation in research, which informs new drug treatment options, and their ability to help other patients in the future. Together we can improve
long-term cancer care for present and future patients.

In partnership with the Oncology Research Information Exchange Network (ORIEN), M2GEN brings together key stakeholders in cancer research to accelerate clinical trials and discovery. This national network, powered by M2GEN, breaks down silos that can inhibit progress, allows researchers to share information and expertise, and facilitates collaboration amongst top cancer centers. By leveraging our informatics platform, we create an offering that brings real-world evidence to bear on specific research needs.

ORIEN Members are some of the nation’s leading cancer institutions that recognize collaboration and access to data are the keys to cancer discovery. There are currently 18 cancer center members working together to leverage multiple data sources and match patients to targeted treatments. To learn more about ORIEN and its' Members, please visit the ORIEN website.

Our ORIEN Members:

Orien_logo_4C_TCC_F

M2GEN's Total Cancer Care is a protocol implemented by ORIEN Members, where patients give consent to the use of their clinical data and tissue specimens for molecular data generation, providing a unique opportunity to learn from patients throughout their lifetime.

Through TCC, patients have provided consent to be studied and re-contacted, making them an active partner in research and enabling the potential to match and enroll them in clinical trials. The ability to correlate targets with response and outcomes data enables the development of novel targets and diagnostics.

My TCC™ provides information and educational materials to patients who have consented to be part of the Total Cancer Care study by sharing what is being learned about cancer through ORIEN TCC.

To learn more, visit: orientcc.org

Advancing Cancer Research, Together

Biopharmaceutical companies play a vital role in the fight against cancer, from researching new targets to developing innovative clinical trials and ultimately bringing new medicines to the market. By leveraging our Oncology Research Information Exchange Network (ORIEN) database to support their efforts, we help our pharma partners reduce research and discovery costs, perform more effective clinical trials, and accelerate drug development timelines.

Accelerating Clinical Development by Anticipating Patient Need

By taking a proactive approach to studying the molecular and clinical nature of a patient’s disease and anticipating need for clinical trials, we can accelerate drug development timelines.

We provide biopharmaceutical companies unparalleled insights into patients' clinical and molecular data that extends beyond the treatment window, giving broader context to health and outcomes and a unique view into how cancer impacts people differently. This accelerates cancer research and helps companies make more informed decisions around clinical trial structuring and development, maximizing the value of the data in our network.